• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Estimation of hydrogen sulfide from crude petroleum: a unique invention using a simple chemosensor?
  Shampa Kundu,Prithidipa Sahoo New J. Chem., 2019,43, 12369-12374
• 3. Distribution pattern and allocation of defects in hydrogenated ZnO thin films?
  Vitaly Gurylev,Chung-Yi Su,Tsong-Pyng Perng Phys. Chem. Chem. Phys., 2016,18, 16033-16038
• 4. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

Introduction to 4-2-(Methylamino)acetyl-2-piperazinonehydrochloride (CAS No: 1220017-36-6)

4-2-(Methylamino)acetyl-2-piperazinonehydrochloride, identified by its CAS number 1220017-36-6, is a compound of significant interest in the field of pharmaceutical chemistry and biochemistry. This compound belongs to the piperazine class of heterocyclic amines, which are widely recognized for their diverse biological activities and utility in drug design. The presence of both an acetyl group and a methylamino substituent in its molecular structure imparts unique chemical and pharmacological properties, making it a valuable scaffold for medicinal chemistry investigations.

The molecular structure of 4-2-(Methylamino)acetyl-2-piperazinonehydrochloride consists of a piperazine ring substituted at the 2-position with an acetyl group, further modified at the 4-position with a methylamino group. This arrangement creates a molecule with potential interactions with various biological targets, including enzymes and receptors. The hydrochloride salt form enhances the solubility and stability of the compound, facilitating its use in both in vitro and in vivo studies.

In recent years, there has been growing interest in exploring the pharmacological potential of piperazine derivatives due to their ability to modulate neurotransmitter systems. Specifically, compounds containing the piperazine moiety have shown promise in the treatment of neurological disorders, such as depression, anxiety, and schizophrenia. The unique combination of functional groups in 4-2-(Methylamino)acetyl-2-piperazinonehydrochloride suggests that it may exhibit potent effects on these systems, making it a compelling candidate for further investigation.

One of the most exciting areas of research involving 4-2-(Methylamino)acetyl-2-piperazinonehydrochloride is its potential as an intermediate in the synthesis of novel therapeutic agents. The acetyl group and methylamino moiety provide reactive sites that can be modified through various chemical transformations, allowing for the creation of derivatives with tailored biological activities. For instance, researchers have explored the use of this compound in developing new antipsychotic and antidepressant drugs, leveraging its structural features to enhance binding affinity and selectivity.

Recent studies have also highlighted the role of 4-2-(Methylamino)acetyl-2-piperazinonehydrochloride in modulating enzyme activity. Piperazine derivatives are known to interact with enzymes such as monoamine oxidase (MAO) and cyclooxygenase (COX), which are crucial in regulating neurotransmitter levels and inflammatory responses. The presence of both an acetyl group and a methylamino substituent in 4-2-(Methylamino)acetyl-2-piperazinonehydrochloride may enhance its ability to influence these enzymatic pathways, offering potential therapeutic benefits.

The synthesis of 4-2-(Methylamino)acetyl-2-piperazinonehydrochloride involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Common synthetic routes include condensation reactions between appropriate precursors followed by functional group modifications. Advances in synthetic methodologies have enabled more efficient production processes, making it feasible to conduct large-scale studies and clinical trials.

In terms of pharmacokinetic properties, 4-2-(Methylamino)acetyl-2-piperazinonehydrochloride exhibits characteristics that make it suitable for oral administration. Its hydrochloride salt form improves bioavailability, allowing for effective delivery to target tissues. Additionally, preliminary pharmacokinetic studies suggest that the compound has a moderate half-life, which could be advantageous for therapeutic applications requiring sustained activity.

The safety profile of 4-2-(Methylamino)acetyl-2-piperazinonehydrochloride is another critical aspect that has been evaluated through preclinical studies. These investigations have focused on assessing toxicity, irritation potential, and other adverse effects. While preliminary results are promising, further research is needed to fully characterize the safety margins before human trials can be initiated.

One notable application of 4-2-(Methylamino)acetyl-2-piperazinonehydrochloride is its use as a research tool in drug discovery programs. Researchers utilize this compound as a starting material to develop libraries of derivatives with enhanced pharmacological properties. High-throughput screening techniques combined with computational modeling have accelerated the process of identifying promising candidates for further development.

The future directions for research on 4-2-(Methylamino)acetyl-2-piperazinonehydrochloride include exploring its potential in treating neurodegenerative diseases such as Alzheimer's and Parkinson's. The ability of piperazine derivatives to modulate neurotransmitter systems makes them attractive candidates for addressing these conditions. Additionally, investigating the compound's interactions with other biological targets may uncover new therapeutic opportunities beyond traditional applications.

In conclusion,4-2-(Methylamino)acetyl-2-piperazinonehydrochloride (CAS No: 1220017-36-6) is a versatile compound with significant potential in pharmaceutical research and development. Its unique molecular structure and pharmacological properties make it a valuable tool for designing novel therapeutic agents targeting neurological disorders and other diseases. As research continues to uncover new applications for this compound,4-2-(Methylamino)acetyl-2-piperazinonehydrochloride is poised to play an important role in advancing medical science.

• 59702-07-7(1-Methylpiperazin-2-one)
• 3027-05-2(1,4-Diacetylpiperazine-2,5-dione)
• 34770-60-0(4-Methylpiperazin-2-one)
• 155595-73-6(4-ethylpiperazin-2-one)
• 5076-82-4(Sarcosine anhydride)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)